- Home
- GMM vs MCRB Comparison
GMM vs MCRB Comparison
Compare GMM & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- MCRB
- Stock Information
- Founded
- GMM 2017
- MCRB 2010
- Country
- GMM China
- MCRB United States
- Employees
- GMM N/A
- MCRB N/A
- Industry
- GMM
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- GMM
- MCRB Health Care
- Exchange
- GMM Nasdaq
- MCRB Nasdaq
- Market Cap
- GMM 70.8M
- MCRB 72.0M
- IPO Year
- GMM 2023
- MCRB 2015
- Fundamental
- Price
- GMM $2.79
- MCRB $7.01
- Analyst Decision
- GMM
- MCRB Hold
- Analyst Count
- GMM 0
- MCRB 5
- Target Price
- GMM N/A
- MCRB $73.67
- AVG Volume (30 Days)
- GMM 25.2K
- MCRB 93.5K
- Earning Date
- GMM 06-10-2025
- MCRB 05-07-2025
- Dividend Yield
- GMM N/A
- MCRB N/A
- EPS Growth
- GMM 62.17
- MCRB N/A
- EPS
- GMM 6.37
- MCRB 8.98
- Revenue
- GMM $41,360,953.00
- MCRB N/A
- Revenue This Year
- GMM N/A
- MCRB N/A
- Revenue Next Year
- GMM N/A
- MCRB N/A
- P/E Ratio
- GMM $0.44
- MCRB $0.84
- Revenue Growth
- GMM 53.82
- MCRB N/A
- 52 Week Low
- GMM $1.69
- MCRB $6.53
- 52 Week High
- GMM $15.60
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- GMM 51.23
- MCRB 39.05
- Support Level
- GMM $2.64
- MCRB $6.84
- Resistance Level
- GMM $2.99
- MCRB $7.33
- Average True Range (ATR)
- GMM 0.31
- MCRB 0.57
- MACD
- GMM 0.02
- MCRB 0.10
- Stochastic Oscillator
- GMM 51.72
- MCRB 29.44
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.